Equities

Genedrive PLC

GDR:LSE

Genedrive PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)1.73
  • Today's Change0.025 / 1.47%
  • Shares traded21.97m
  • 1 Year change-86.93%
  • Beta-1.0842
Data delayed at least 20 minutes, as of Jul 05 2024 16:29 BST.
More ▼

Profile data is unavailable for this security.

About the company

genedrive plc is a United Kingdom-based pharmacogenetic testing company. The Company is engaged in developing and commercializing a rapid, versatile, simple to use and robust point-of-need pharmacogenetic platform for the diagnosis of genetic variations. The Company’s products include Genedrive MT-RNR1 ID Kit, Genedrive System, and Genedrive CYP2C19 ID Kit. The Company’s flagship product Genedrive MT-RNR1 ID Kit is a single-use disposable cartridge that circumvents the requirement for cold chain logistics by providing temperature stable reagent test kits for use on their proprietary test platform. The Genedrive System is a rapid thermocycler and signal detection system, enabling PCR and isothermal based amplification techniques. It is a semi- automated system used for qualitative in vitro molecular diagnostic tests. Its Genedrive CYP2C19 ID Kit Molecular point-of-care test for rapid CYP2C19 genotyping in time-critical emergency care settings.

  • Revenue in GBP (TTM)272.00k
  • Net income in GBP-5.00m
  • Incorporated2007
  • Employees43.00
  • Location
    Genedrive PLC48 Grafton StreetMANCHESTER M13 9XXUnited KingdomGBR
  • Phone+44 16 1989 0245Fax+44 16 1989 0262
  • Websitehttp://www.genedriveplc.com/
More ▼

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
Surgical Innovations Group Plc12.01m-509.00k5.13m101.005.13m101.00
Myhealthchecked PLC10.98m-159.00k5.20m10.005.20m10.00
Rua Life Sciences PLC1.87m-1.87m6.83m40.006.83m40.00
Cambridge Nutritional Sciences PLC9.05m-3.21m8.69m91.008.69m91.00
Feedback plc886.00k-3.49m9.13m24.009.13m24.00
Genedrive PLC272.00k-5.00m9.37m43.009.37m43.00
Proteome Sciences plc5.03m-2.44m11.07m35.0011.07m35.00
Inspiration Healthcare Group PLC37.63m-6.32m11.94m210.0011.94m210.00
Genincode PLC2.16m-7.02m12.17m36.0012.17m36.00
Abingdon Health PLC5.34m-2.24m12.99m82.0012.99m82.00
Data as of Jul 05 2024. Currency figures normalised to Genedrive PLC's reporting currency: UK Pound GBX

Institutional shareholders

24.85%Per cent of shares held by top holders
HolderShares% Held
Peel Hunt LLPas of 24 Jun 202454.27m17.58%
Hargreaves Lansdown Asset Management Ltd.as of 01 Jan 20225.48m1.78%
Jarvis Investment Management Ltd.as of 14 Jun 20232.95m0.96%
IG Markets Ltd.as of 01 Jan 20222.74m0.89%
Rathbones Investment Management Ltd.as of 01 Jan 20222.35m0.76%
HSBC Global Asset Management (UK) Ltd.as of 01 Jan 20222.21m0.71%
BGF Investment Management Ltd.as of 05 Feb 20211.91m0.62%
Walker Crips Investment Management Ltd.as of 01 Jan 20221.90m0.61%
M&G Investment Management Ltd.as of 05 Feb 20201.76m0.57%
Unicorn Asset Management Ltd.as of 30 Jun 20241.15m0.37%
More ▼
Data from 31 Mar 2024 - 01 Jul 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.